Biologics-based degraders - an expanding toolkit for targeted-protein degradation.
Biologics-based degraders - an expanding toolkit for targeted-protein degradation.
复制标题
DOI:
10.1016/j.copbio.2022.102807
复制
发表时间:
2022-09
影响因子:
7.7
通讯作者:
D. VanDyke;Jonathan D. Taylor;Kyle J Kaeo;J. Hunt;Jamie B. Spangler
中科院分区:
文献类型:
--
作者:
D. VanDyke;Jonathan D. Taylor;Kyle J Kaeo;J. Hunt;Jamie B. Spangler
HighlightsTargeted-protein degradation supports fundamental discovery and drug development.Biologics-based degraders target intracellular, extracellular, and membrane proteins.Biologic approaches facilitate tissue-targeting and isoform-specific degradation.Biologics-based degraders utilize both proteasomal and lysosomal degradation.New strategies are being developed to deliver biologics-based degraders in vivo.Targeted protein degradation (TPD) is a broadly useful proteome editing tool for biological research and therapeutic development. TPD offers several advantages over functional inhibition alone, including the ability to target previously undruggable proteins and the substantial and sustained knockout of protein activity. A variety of small molecule approaches hijack endogenous protein degradation machinery, but are limited to proteins with a cytosolic domain and suitable binding pocket. Recently, biologics-based methods have expanded the TPD toolbox by allowing access to extracellular and surface-exposed proteins and increasing target specificity. Here, we summarize recent advances in the use of biologics to deplete proteins through either the ubiquitin–proteasome system or the lysosomal degradation pathway, and discuss routes to their effective delivery as potential therapeutic interventions.